论文部分内容阅读
脑胶质瘤是中枢神经系统最常见的肿瘤,经目前“标准治疗”(即手术+放疗+全身化疗)后,恶性胶质瘤患者的中位生存期仍不足1年。临床及CT观察均证实,几乎所有的恶性胶质瘤术后均要复发,90％以上的复发位于原发灶的2cm以内。虽然目前立体定向放射外科,间质内放疗及超分割放疗等技术相继应用于临床,为胶质瘤的治疗提供了新的手段,但当肿瘤体积较大,界限不清,形状不规则时,仍难以收到满意的效果,同时还有放射性脑损害的可能,加之对技术条件、设备要求高,临床推广应用有一定困难。而常规全身化疗由于血脑屏障的限制,多数化疗药物难以在颅内达到足够浓度,且毒副作用较严重,同时化疗药物
Gliomas are the most common tumors of the central nervous system. The median survival of patients with malignant gliomas is still less than 1 year after the current “standard treatment” (ie surgery + radiotherapy + systemic chemotherapy). Clinical and CT confirmed that almost all of the malignant gliomas have recurrence after surgery, more than 90% of the recurrence in the primary tumor within 2cm. Although the current stereotactic radiosurgery, interstitial radiotherapy and hyperfractionation radiotherapy and other technologies have been applied to clinical treatment of glioma provides a new means, but when the tumor volume larger, ill-defined, irregular shape, Still difficult to receive satisfactory results, but also the possibility of radioactive brain damage, combined with the technical conditions, high equipment requirements, the clinical application of a certain difficulty. Conventional systemic chemotherapy due to the limitations of the blood-brain barrier, the majority of chemotherapy drugs in the brain is difficult to achieve adequate concentration, and more serious side effects, while chemotherapy drugs